Novo Nordisk x Eli Lilly advertising dispute: what is actually on the record about Zepbound and Mounjaro

The Novo Nordisk and Eli Lilly advertising dispute has been bouncing around social media, and posts about who is "winning" the tirzepatide versus semaglutide fight spread faster than the documents behind them. This post separates what is on the public record from what is only a claim, and explains what the whole situation means for people following tirzepatide in Brazil.

Why two companies are fighting over ads

Mounjaro and Zepbound contain the same molecule, tirzepatide, made by Eli Lilly. Ozempic and Wegovy contain a different molecule, semaglutide, made by Novo Nordisk. Tirzepatide acts on two hormone receptors, GIP and GLP-1, while semaglutide acts on GLP-1 alone. That difference is why people compare the two, and why the names get mixed up in conversations.

Brand names and approved uses change from country to country. In the United States, Mounjaro is approved for type 2 diabetes and Zepbound for chronic weight management, with Ozempic and Wegovy following a similar split for semaglutide. Don't assume the US label applies in Brazil. Check the brand names, the registered indications, and the current bula on the Anvisa records.

The fight is about marketing because both companies sell to the same two groups: people living with obesity who want treatment, and the doctors who write the prescriptions. When two brands compete for the same patient and the same prescriber, every claim about better results or fewer side effects carries commercial weight. Advertising disputes are common in regulated markets. Still, the exact content of any specific dispute has to be confirmed case by case, because headlines usually shorten what was actually argued.

Timeline of what is publicly documented

Instead of building a timeline from memory or from viral posts, start with the primary records. For this kind of dispute, those are the press releases each company publishes on its investor relations page, the case files and decisions of advertising self-regulatory bodies, and any court filings that are open to the public. Each one is a different kind of document, and each carries different weight.

Keep three categories apart. A decision is a ruling by a body with authority to make one. An allegation is one party's claim that another party's ad is misleading, and it stays an allegation until someone rules on it. Press commentary is what journalists, analysts, or executives say, which can be useful context but is not a finding. Many viral posts blend all three into one sentence, and that blend is where most of the confusion starts.

The forum matters too. In the United States, the National Advertising Division of BBB National Programs reviews challenges between competitors and publishes its decisions. It is a self-regulatory body, so its recommendations are not court judgments. A company can appeal to the National Advertising Review Board, and when a company refuses to comply, the matter can be referred to the Federal Trade Commission. A court case runs on a separate track and can produce a binding judgment. None of these outcomes automatically applies in Brazil, where Anvisa oversees medicine advertising and CONAR handles self-regulation of advertising in general.

Some steps may still be open when you read this. An appeal can be pending, a new challenge can be filed, or a court can be waiting on a motion. Before you repeat any date or outcome, look for the latest update on the case page and note its date. If you can't find a dated update, treat the status as unverified.

What each side is claiming

Claims in this kind of dispute usually revolve around comparisons: which drug produces more weight loss, which one has a better tolerability profile, which one suits certain patients. Read them carefully. A slogan that says one drug beats another is a short version of a longer statement, and the short version rarely includes the population, the dose, the length of the study, or the outcome that was measured.

That is why head-to-head studies matter. A head-to-head trial compares two drugs directly under the same study conditions. One such trial, SURMOUNT-5, compared tirzepatide with semaglutide in adults with obesity and was published in the New England Journal of Medicine. To know what it actually measured, read the primary results section rather than a secondary summary. Check who was enrolled, which doses were used, how long participants were followed, and what the primary endpoint was. Those details decide how far the findings can reasonably be stretched.

Then ask whether the ad cites the study itself or a simplified version of it. A trial in one population over one period may support a narrower statement than the ad makes. A study that measured one endpoint says little about another. Whether a claim proves superiority depends on those details, and that technical reading will serve you far better than picking a team between the two brands.

The rules that apply, here and in the US

Advertising for prescription medicines follows different rules in each country. In the US, the FDA oversees prescription drug promotion, and the FTC handles many advertising claims. In Brazil, Anvisa regulates medicine advertising, and its rules restrict direct advertising to the public for products that require a prescription. Check the current Anvisa rule on the agency's website before you cite any resolution number or date, because rules get updated.

Brazilian readers see American ads on Instagram, YouTube, and news sites every day. Seeing an ad online doesn't tell you whether that ad would be allowed here. The same campaign can be legal in one country and restricted in another, and the platform where you saw it doesn't change that. Also check the Anvisa news page for any public statement on this specific dispute. If you find none, don't assume the agency has taken a position.

This section is general information, not legal advice. If you need to know whether a specific ad or company action is lawful, talk with a lawyer who works with health and advertising law in Brazil.

What this means for someone in Brazil

Reading manufacturer material without getting lost takes practice. If you want a step-by-step approach, our guide on reading manufacturer information on TirzeBlog walks through the basics. A public fight between manufacturers can create confusion about price, availability, and expectations. A headline calling one brand better can push people to ask for a name that isn't registered locally, or to expect results their doctor never discussed. Pause before acting on a headline. Price and supply in Brazil depend on local registration, pharmacies, and distributors, not on a US campaign.

An advertising dispute between companies does not, on its own, change the approved indication, dose, or safety profile of a product in Brazil. Those points come from the registration and the current bula, and any change to them will appear in those records. Whether tirzepatide is appropriate is a medical decision that depends on your history, your exams, the other medicines you take, and follow-up with a doctor who can monitor you. A comparison ad can't replace that conversation. Tirzepatide may help some people with weight loss, but it is not a cure and it isn't the right choice for everyone.

What is still unknown and how to follow updates

Several questions remain unanswered in public. Does the dispute still have open proceedings, and at which stage? Did either company appeal or file a new challenge? Has any regulator outside the US commented on the claims? Did either company change an ad after a decision? Until primary sources answer these, treat any claim that depends on them as unconfirmed.

To follow updates, start with primary sources: the investor relations pages of Eli Lilly and Novo Nordisk, the public case databases of BBB National Programs, and the decision records of CONAR for anything connected to Brazil. Specialist outlets that cover advertising law usually report decisions quickly and link to the original documents. Social media posts often skip the link or compress a ruling into one line, and that line can flip the outcome. When the TirzeBlog team covers stories like this, we try to open the document a story cites before trusting the headline, and you can do the same.

Quick reading checklist before you share

Before you share anything about this dispute, ask four questions. First, is the source primary, such as a company release, a published decision, or a court record, or is it a repost of someone else's summary? Second, has a decision been made, or is the claim still an allegation? Third, does the forum's ruling apply in Brazil, or does it only bind parties within its own jurisdiction? Fourth, does the cited study have the same population, dose, and outcome as the sentence in the ad? If you can't answer one of them, hold off. Health content travels faster than corrections, so keep the source link in hand before you post. That is the standard we try to hold ourselves to at TirzeBlog.

FAQ

Is Mounjaro the same as Zepbound?

Both contain tirzepatide, made by Eli Lilly. The brand names and approved uses differ by country and indication, so check the label that applies where you live.

Is tirzepatide better than semaglutide?

Head-to-head trials can compare them directly, but the answer depends on the population, dose, study length, and outcome measured. A single headline can't settle that question.

Is Mounjaro advertising allowed in Brazil?

Anvisa restricts advertising of prescription medicines to the public. Check the current Anvisa rule, because seeing an ad made abroad doesn't mean that ad is permitted here.

Has a court ruled on the Novo Nordisk and Eli Lilly dispute?

Check the latest update in the primary sources, including company investor pages and public decision databases. If you can't find a dated record, treat the status as unverified.

Can I get tirzepatide without a prescription?

No. Tirzepatide is a prescription medicine, so it requires an evaluation and a prescription from a doctor who can follow your health.

Sources

• Eli Lilly and Company, Investor Relations
• Novo Nordisk, official website and investor information
• U.S. Food and Drug Administration (FDA)
• Federal Trade Commission (FTC)
• BBB National Programs, National Advertising Division
• Anvisa, Agência Nacional de Vigilância Sanitária
• CONAR, Conselho Nacional de Autorregulamentação Publicitária
• New England Journal of Medicine